-
公开(公告)号:US20240139256A1
公开(公告)日:2024-05-02
申请号:US18479774
申请日:2023-10-02
Inventor: Sarah HIMMERICH , Nathaniel BEARDSLEY , Annie ARMSTRONG SMELTER , Nathan MEYER , Ravi VAIDYANATHAN , Cara RIEGER
CPC classification number: A61K35/33 , A61P9/04 , C12N5/0657 , C12N5/0697 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/415 , C12N2506/45
Abstract: Provided herein are methods for producing quiescent cardiac fibroblast cells from pluripotent stem cells. Further provided herein are microtissue compositions comprising the cardiac fibroblast cells with endothelial cells and cardiomyocytes.
-
公开(公告)号:US20250011714A1
公开(公告)日:2025-01-09
申请号:US18886115
申请日:2024-09-16
Applicant: FUJIFILM Cellular Dynamics, Inc.
Inventor: Nathan MEYER , Lucas CHASE , Casey STANKEWICZ
Abstract: Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and/or CD90 positive cells from a starting population of RPE cells.
-
公开(公告)号:US20220033770A1
公开(公告)日:2022-02-03
申请号:US17493533
申请日:2021-10-04
Applicant: FUJIFILM Cellular Dynamics, Inc.
Inventor: Nathan MEYER , Lucas CHASE , Casey STANKEWICZ
Abstract: Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and/or CD90 positive cells from a starting population of RPE cells.
-
公开(公告)号:US20210238546A1
公开(公告)日:2021-08-05
申请号:US17049018
申请日:2019-04-22
Applicant: FUJIFILM Cellular Dynamics, Inc.
Inventor: Lucas CHASE , Kyle WALLACE , Benjamin MELINE , Andrew DIAS , Brandon SHELLEY , Marisa FENN , Debjani PHILLIPS , Matthew STERNFELD , Nathan MEYER
IPC: C12N5/079 , A61K35/30 , C12N5/0793 , G01N33/68
Abstract: Provided herein are methods of producing a photoreceptor precursor (PRP) cell population derived from stem cells. Further provided herein are methods of using the PRP cell populations, such as for therapeutics.
-
-
-